Tela Bio, Inc. - Understand $tela stock

$TELA Market Cap: $113.8 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$68.65M

TTM

Gross Margin

68.33%

TTM

Net Earnings

-$41.52M

TTM

Current Assets

$44.13M

Q3 2024

Current Liabilities

$16.86M

Q3 2024

Current Ratio

261.79%

Q3 2024

Total Assets

$53.02M

Q3 2024

Total Liabilities

$59.29M

Q3 2024

Book Value

-$6.272M

Q3 2024

Cash

$17.30M

Q3 2024

P/E

-2.741

Nov 29, 2024 EST

Free Cash Flow

-$46.04M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$58.45M	$41.42M	$29.46M	$18.21M	$15.45M	$8.270M	$4.250M
YoY Change	41.13%	40.58%	61.77%	17.91%	86.77%	94.59%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017
Revenue	$58.45M	$41.42M	$29.46M	$18.21M	$15.45M	$8.270M	$4.250M
Cost Of Revenue	$18.34M	$14.37M	$10.65M	$6.980M	$6.170M	$5.330M	$1.710M
Gross Profit	$40.11M	$27.04M	$18.81M	$11.23M	$9.272M	$2.940M	$2.530M
Gross Profit Margin	68.62%	65.3%	63.85%	61.68%	60.03%	35.55%	59.53%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017
Selling, General & Admin	$74.57M	$57.11M	$41.52M	$32.25M	$24.28M	$18.55M	$13.67M
YoY Change	30.56%	37.55%	28.73%	32.83%	30.91%	35.7%
% of Gross Profit	185.9%	211.19%	220.7%	287.11%	261.9%	630.95%	540.32%
Research & Development	$9.619M	$8.937M	$6.743M	$4.255M	$4.151M	$4.340M	$5.790M
YoY Change	7.63%	32.54%	58.47%	2.51%	-4.35%	-25.04%
% of Gross Profit	23.98%	33.05%	35.84%	37.88%	44.77%	147.62%	228.85%
Depreciation & Amortization	$400.0K	$400.0K	$200.0K	$200.0K	$300.0K	$1.250M	$760.0K
YoY Change	0.0%	100.0%	0.0%	-33.33%	-76.0%	64.47%
% of Gross Profit	1.0%	1.48%	1.06%	1.78%	3.24%	42.52%	30.04%
Operating Expenses	$84.19M	$66.05M	$48.26M	$36.51M	$28.43M	$22.89M	$19.46M
YoY Change	27.46%	36.85%	32.2%	28.4%	24.22%	17.63%
Operating Profit	-$44.08M	-$39.01M	-$29.45M	-$25.28M	-$19.16M	-$19.95M	-$16.93M
YoY Change	12.99%	32.45%	16.52%	31.9%	-3.95%	17.84%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017
Interest Expense	$5.223M	$4.051M	$3.597M	$3.564M	$3.609M	-$1.800M	-$4.560M
YoY Change	28.93%	12.62%	0.93%	-1.25%	-300.5%	-60.53%
% of Operating Profit
Other Income/Expense, Net	-$2.589M	-$5.289M	-$3.825M	-$3.519M	-$3.263M	$310.0K	$150.0K
YoY Change	-51.05%	38.27%	8.7%	7.85%	-1152.58%	106.67%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017
Pretax Income	-$46.66M	-$44.30M	-$33.28M	-$28.79M	-$22.43M	-$21.09M	-$21.33M
YoY Change	5.35%	33.12%	15.58%	28.35%	6.35%	-1.13%
Income Tax						$0.00	$0.00
% Of Pretax Income
Net Earnings	-$46.66M	-$44.30M	-$33.28M	-$28.79M	-$22.43M	-$21.09M	-$21.33M
YoY Change	5.35%	33.12%	15.57%	28.4%	6.33%	-1.13%
Net Earnings / Revenue	-79.83%	-106.95%	-112.94%	-158.1%	-145.18%	-255.02%	-501.88%
Basic Earnings Per Share	-$2.04	-$2.72	-$2.30	-$2.23	-$17.10
Diluted Earnings Per Share	-$2.04	-$2.72	-$2.30	-$2.23	-$17.10	-$1.916M	-$1.937M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017
Cash & Short-Term Investments	$46.73M	$42.02M	$43.93M	$74.39M	$54.59M	$17.28M	$11.35M
YoY Change	11.21%	-4.35%	-40.95%	36.27%	215.91%	52.25%
Cash & Equivalents	$46.73M	$42.02M	$43.93M	$74.39M	$45.30M	$17.28M	$11.35M
Short-Term Investments				$0.00	$9.290M
Other Short-Term Assets	$2.098M	$2.015M	$3.232M	$2.240M	$2.310M	$330.0K	$430.0K
YoY Change	4.12%	-37.65%	44.29%	-3.03%	600.0%	-23.26%
Inventory	$13.16M	$11.79M	$7.658M	$3.910M	$4.600M	$4.350M	$1.820M
Prepaid Expenses
Receivables	$9.737M	$6.621M	$4.234M	$2.680M	$2.840M	$1.300M	$760.0K
Other Receivables	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$71.73M	$62.45M	$59.06M	$83.23M	$64.33M	$23.25M	$14.35M
YoY Change	14.86%	5.74%	-29.05%	29.38%	176.69%	62.02%
Property, Plant & Equipment	$3.938M	$2.909M	$1.186M	$630.0K	$680.0K	$760.0K	$1.160M
YoY Change	35.37%	145.28%	88.25%	-7.35%	-10.53%	-34.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$265.0K					$0.00	$20.00K
YoY Change						-100.0%
Total Long-Term Assets	$6.322M	$5.408M	$3.489M	$3.230M	$3.590M	$3.980M	$1.180M
YoY Change	16.9%	55.0%	8.02%	-10.03%	-9.8%	237.29%
Total Assets	$78.05M	$67.86M	$62.54M	$86.46M	$67.92M	$27.23M	$15.53M
YoY Change
Accounts Payable	$1.667M	$1.534M	$2.414M	$650.0K	$3.170M	$3.420M	$1.510M
YoY Change	8.67%	-36.45%	271.38%	-79.5%	-7.31%	126.49%
Accrued Expenses	$15.30M	$10.87M	$8.161M	$5.950M	$3.530M	$5.150M	$1.800M
YoY Change	40.77%	33.18%	37.16%	68.56%	-31.46%	186.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due						$0.00	$910.0K
YoY Change						-100.0%
Total Short-Term Liabilities	$16.97M	$12.40M	$10.58M	$6.610M	$6.710M	$9.560M	$6.150M
YoY Change	36.8%	17.29%	59.98%	-1.49%	-29.81%	55.45%
Long-Term Debt	$40.52M	$39.92M	$31.49M	$30.83M	$30.24M	$31.37M	$5.310M
YoY Change	1.5%	26.75%	2.14%	1.95%	-3.6%	490.77%
Other Long-Term Liabilities	$1.685M	$1.231M	$380.0K		$0.00	$10.00K	$900.0K
YoY Change	36.88%	223.95%			-100.0%	-98.89%
Total Long-Term Liabilities	$42.20M	$41.15M	$31.87M	$30.83M	$30.24M	$31.38M	$6.210M
YoY Change	2.56%	29.1%	3.38%	1.95%	-3.63%	405.31%
Total Liabilities	$59.17M	$53.55M	$42.45M	$37.43M	$36.96M	$40.94M	$12.35M
YoY Change	10.49%	26.16%	13.4%	1.27%	-9.72%	231.5%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019
Basic Shares Outstanding	22.87M	16.27M	14.47M	12.93M	1.766M
Diluted Shares Outstanding	22.87M	16.27M	14.47M	12.93M	1.766M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $113.83 Million

About TELA Bio, Inc.

TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 227 full-time employees. The company went IPO on 2019-11-08. The firm is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall reconstruction. Its OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair. The firm's OviTex products include OviTex 1S, OviTex 2S, and OviTex LPR. Its second portfolio of products, the OviTex PRS Reinforced Tissue Matrix (OviTex PRS), addresses unmet needs in plastic and reconstructive surgery. OviTex PRS is indicated for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft-tissue repair.

Industry: Surgical & Medical Instruments & Apparatus Peers: Xtant Medical Holdings, Inc. RxSight, Inc. Sanara MedTech Inc. United Health Products, Inc. ORASURE TECHNOLOGIES INC RETRACTABLE TECHNOLOGIES INC VOLITIONRX LTD SmileDirectClub, Inc. UTAH MEDICAL PRODUCTS INC